| answer text |
<p><del class="ministerial">For unbranded generics the Government relies on completion
to keep prices down which generally works well and has led to low prices of these
medicines. We alert the Competition and Markets Authority (CMA) when we believe that
competition does not work. In the case of liothyronine, the CMA is currently investigating
Concordia’s potential abuse of its dominant position to overcharge the National Health
Service for liothyronine.</del></p><p> </p><p><del class="ministerial">In primary
care community pharmacies are incentivised to source products at the lowest possible
cost by allowing them to retain the medicines margin (the difference between what
the NHS reimburses a pharmacy for a product and how much the pharmacy purchases it
for) up to £800 million in England. In secondary care, competitive tenders ensure
value-for-money to the NHS.</del></p><p><ins class="ministerial"> <p><ins class="ministerial">NHS
England is not responsible for approving medicines. The Medicines and Healthcare products
Regulatory Agency (MHRA) is responsible for ensuring that medicines and medical devices
work and are acceptably safe. The National Institute for Health and Care Excellence
makes recommendations for the National Health Service on whether medicines and other
treatments represent a clinically and cost effective use of NHS resources.</ins></p><p><ins
class="ministerial"><strong> </strong></ins></p><p><ins class="ministerial">A list
of medicines licensed by the MHRA for the treatment of thyroid conditions is attached.
The list is split into two sections because thyroid conditions can be split into either
those associated with an overactive thyroid (hyperthyroidism), or an underactive thyroid
(hypothyroidism). The list contains only those medicines licensed for overactive and
underactive thyroid. It should be noted that not all of the medicines listed will
be available on the market at any one time. </ins></p></ins></p>
|
|
